Plain-English translation of NCT06176508 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help reduce joint swelling, pain, and psoriasis symptoms in adults with psoriatic arthritis. Researchers want to find out whether this medication works better than a placebo (dummy pill) and compare it to an existing treatment. The trial will also help doctors figure out the best dose to use in future studies.
Psoriatic arthritis can be difficult to treat, and some patients don't respond well to current medications or can't tolerate them. This study aims to find a new treatment option that might help people whose condition isn't adequately controlled by existing therapies.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication at one of two doses, a placebo, or an existing arthritis medication (tofacitinib). You'll take your assigned treatment and attend clinic visits for screening, baseline assessment, and follow-up evaluations where doctors will check your joint swelling, tenderness, skin symptoms, and blood work. The study involves 160 adults across multiple medical centers.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Hansoh BioMedical R&D Company
Enrollment target
~160 participants
Started
February 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hejian Zou, PhD
Huashan Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.